Table 2. Mean intrasubject diversity for the 11 study participants, by genomic region. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects.

Slides:

Advertisements

Similar presentations

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT-1 and HIV Coinfection NIAID ERADICATE Trial Phase 2a Treatment Naïve and Treatment.

Advertisements

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.

Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Antiretroviral Therapy on Viral Load, CD4.

Phase 3 Treatment-Naïve and Treatment-Experienced

Treatment-Naïve Adults

Figure 3 Escape into the cytosol and subsequent intracellular replication during an infection of J774 macrophages with Listeria monocytogenes ΔactA (diamonds),

Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.

Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response.

International Journal of Infectious Diseases

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

ARV-trial.com Switch to ATV/r + 3TC ATLAS-M Study.

Table 1. Prevalence of hepatitis B surface antigen (HBsAg) in west African cohorts from different countries. From: Low Genetic Diversity despite Hyperendemicity.

Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.

Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.

Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.

Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients ASTRAL-5

Figure 1. Prevalence of undocumented hepatitis C virus (HCV) infection, by age, race, and sex in 4713 emergency department patients, From: Evaluation.

From: Postinfectious Irritable Bowel Syndrome

From: Treatment of Refractory Whipple Disease with Interferon-γ

Table 1 Baseline (before receipt of antiretroviral prophylaxis) characteristics of the pregnant women (transmitting or nontransmitting mothers included.

Figure 1 Annual per-capita consumption of all fermented milks and yogurt only in selected countries in Europe and North America [3, 4]. From: Probiotic.

DOES HIV/ HEPATITIS COINFECTION AFFECT PEOPLE ACCESSING CARE FOR HIV

Figure 3. Changes from baseline in activated CD4+ T cells (% CD4+CD25+) during the 52-week intervention period in the.

Association of CD4+ T-lymphocyte counts and new thymic emigrants in HIV-infected children during successful highly active antiretroviral therapy Akihiko.

R. Cavallo Clinical Microbiology and Infection

Volume 39, Issue 6, Pages (December 2003)

Effect of highly active anti-retroviral therapy and hepatitis C virus co-infection on serum levels of pro-inflammatory and immunoregulatory cytokines.

Hepatitis C virus infection

Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response.

Les Lang Gastroenterology Volume 133, Issue 1, (July 2007)

Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following.

Les Lang Gastroenterology Volume 133, Issue 1, (July 2007)

Simeprevir in HIV Coinfection, GT-1 C212 Trial

Phase 3 Treatment Naïve HIV Coinfection

Association of CD209L tandem repeats polymorphism with susceptibility to human immunodeficiency virus-1 infection, disease progression, and treatment.

Virological tools to diagnose and monitor hepatitis C virus infection

A. Zeytinoğlu, S. Erensoy, H. Abacioğlu, A. A. Sayiner, T. Özacar, A

Volume 155, Issue 5, Pages e2 (November 2018)

Peptide insertions in reverse transcriptase pol gene of human immunodeficiency virus type 1 as a rare cause of persistent antiretroviral therapeutic failure

Volume 136, Issue 4, Pages (April 2009)

L. Dubourg Clinical Microbiology and Infection

The allele 4 of neck region liver-lymph node-specific ICAM-3-grabbing integrin variant is associated with spontaneous clearance of hepatitis C virus and.

Epidemiological and virological characteristics of symptomatic acute hepatitis E in Greater Cairo, Egypt E. Delarocque-Astagneau, F. Abravanel, A. Moshen,

Next-generation sequencing technology in clinical virology

Baseline Kidney Function as Predictor of Mortality and Kidney Disease Progression in HIV-Positive Patients Fowzia Ibrahim, MSc, Lisa Hamzah, MRCP, Rachael.

Occupational transmission of hepatitis C virus resulting from use of the same supermarket meat slicer L. Bocket, S. Chevaliez, N. Talbodec, A. Sobaszek,

Hepatitis E virus as a newly identified cause of acute viral hepatitis during human immunodeficiency virus infection P. Colson, C. Dhiver, R. Gérolami

Multiple genotypes and subtypes of hepatitis B and C viruses in Belarus: similarities with Russia and western European influences C.M. Olinger, N.V.

Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients.

Hepatitis B virus in Buenos Aires, Argentina: genotypes, virological characteristics and clinical outcomes S.C. Pezzano, C. Torres, H.A. Fainboim, M.B.

REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR:

New developments in laboratory monitoring of HIV-1 infection

Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response.

Evidence for human immunodeficiency virus and Cryptococcus neoformans interactions in the pro-inflammatory and anti-inflammatory responses in blood during.

Volume 140, Issue 7, Pages (June 2011)

MW polyomavirus and STL polyomavirus present in tonsillar tissues from children with chronic tonsillar disease J. Peng, K. Li, C. Zhang, Q. Jin Clinical.

Genetic diversity of Mycobacterium tuberculosis isolates from foreign-born and Japan- born residents in Tokyo M. Kato-Miyazawa, T. Miyoshi-Akiyama, Y.

Factors related to the chronicity and evolution of hepatitis C infection in patients coinfected by the human immunodeficiency virus R. Pérez-Cano, C.

Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK A. Beloukas, S. King, K. Childs,

Accurate hepatitis C virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection E. Knops, E. Heger Clinical Microbiology.

Control of human cytomegalovirus infection in patients infected with human immunodeficiency virus by high levels of specific CD8+ T-cells D. Lilleri,

Detection of a new subgenotype of hepatitis B virus genotype A in Cameroon but not in neighbouring Nigeria J.M. Hübschen, P.O. Mbah, J.C. Forbi, J.A.

Diversity and evolution of methods and practices for the molecular diagnosis of congenital toxoplasmosis in France: a 4-year survey Y. Sterkers, E. Varlet-Marie,

Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection Lin Shen, MD, Robert F. Siliciano,

Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection Harald Farnik, Christian M. Lange,

Overall trends in CD4 counts and plasma viremia in an urban clinic since the introduction of highly active antiretroviral therapies J.C. Martín, V Soriano,

Phase 3 Treatment-Naïve and Treatment-Experienced

The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.

Figure 1. Unrooted phylogenetic trees for UL73 and UL74 based on amino acid sequences derived from 243 genome ... Figure 1. Unrooted phylogenetic trees.

Presentation transcript:

Table 2. Mean intrasubject diversity for the 11 study participants, by genomic region. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects Initiating Highly Active Antiretroviral Therapy J Infect Dis. 2004;189(8):1472-1481. doi:10.1086/382959 J Infect Dis | © 2004 by the Infectious Diseases Society of America

Table 3. Diversity of hepatitis C virus (HCV) quasi species, by HCV response group. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects Initiating Highly Active Antiretroviral Therapy J Infect Dis. 2004;189(8):1472-1481. doi:10.1086/382959 J Infect Dis | © 2004 by the Infectious Diseases Society of America

Table 4. Correlation between change in hepatitis C virus (HCV) load and change in quasi species parameters. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects Initiating Highly Active Antiretroviral Therapy J Infect Dis. 2004;189(8):1472-1481. doi:10.1086/382959 J Infect Dis | © 2004 by the Infectious Diseases Society of America

Table 5. Correlation between change in CD4 cell count and change in quasi species parameters. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects Initiating Highly Active Antiretroviral Therapy J Infect Dis. 2004;189(8):1472-1481. doi:10.1086/382959 J Infect Dis | © 2004 by the Infectious Diseases Society of America

Table 1. Baseline demographic and virologic characteristics of HIV-hepatitis C virus (HCV)-coinfected subjects, by HCV response group. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects Initiating Highly Active Antiretroviral Therapy J Infect Dis. 2004;189(8):1472-1481. doi:10.1086/382959 J Infect Dis | © 2004 by the Infectious Diseases Society of America

Figure 2. Minimum evolution tree for envelope glycoprotein 1 (E1) consensus sequences. Relevant bootstrap values >70 (of 100) are shown. Reference sequences include hepatitis C virus (HCV) genotype 1a (black circles), HCV genotype 1b (white circles), HCV genotype 1c (gray circle), and HCV non-1 genotypes (white squares). Patients in the HCV increaser or HCV stable group are labeled “INC” or “S”, respectively, followed by the patient no. and no. of the week. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects Initiating Highly Active Antiretroviral Therapy J Infect Dis. 2004;189(8):1472-1481. doi:10.1086/382959 J Infect Dis | © 2004 by the Infectious Diseases Society of America

Figure 1. Median virologic and immunologic data for the hepatitis C virus (HCV) increaser (black symbols) and HCV stable (white symbols) groups at weeks 0, 16, and 48. Squares, CD4 cell count; diamonds, log<sub>10</sub> HIV load; and triangles, log<sub>10</sub> HCV load. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects Initiating Highly Active Antiretroviral Therapy J Infect Dis. 2004;189(8):1472-1481. doi:10.1086/382959 J Infect Dis | © 2004 by the Infectious Diseases Society of America